ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This trial is testing a new investigational antibody (XmAb942) specifically in people with moderately to severely active ulcerative colitis who have not responded to prior therapies. Early‑phase studies determine safety, dosing, and whether a drug shows enough effect to justify larger trials.
Who Should Pay Attention
Adults with moderately to severely active ulcerative colitis (especially those with prior inadequate response or intolerance to UC therapies); clinicians who treat IBD; researchers and patients interested in emerging biologic treatments.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 1, Phase 2
Enrollment270 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
XmAb942 is being tested in a standard early-phase dose-escalation design for safety and dosing in healthy volunteers, followed by a Phase 2 induction/maintenance evaluation in people with moderately to severely active UC who have had an inadequate response or intolerance to prior UC therapies.
The UC part uses modified Mayo score and endoscopic assessment for key efficacy endpoints and includes a 12‑week induction period, a 40‑week maintenance period, and a 24‑week follow‑up. Eligibility excludes other colitis diagnoses and common infectious or immunocompromising conditions.
If you are considering participation, the registry record lists inclusion/exclusion criteria, dose routes (subcutaneous and IV in healthy-participant parts), and trial locations; contact the listed study sites or sponsor for up-to-date enrollment information and risks.
Keep In Mind
This is a registered Phase 1/2 study (recruiting) on ClinicalTrials.gov funded by Xencor, Inc.; as a trial record it describes planned study design and endpoints rather than reporting results. Participation involves standard trial screening and exclusion of other colitis causes; investigational status means safety and efficacy are not yet established.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorXencor, Inc.
Trial IDNCT06619990
Study typeInterventional
Trial phasePhase 1, Phase 2
Enrollment270 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedJul 24, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
This trial is testing duvakitug as a maintenance treatment for people with moderately to severely active ulcerative colitis who responded to an earlier study, which could expand treatment options if later shown to be...
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
This trial tests two investigational agents (eltrekibart and mirikizumab) for moderate–severe ulcerative colitis, which may offer additional treatment options if proven safe and effective. It’s relevant to people whose...